|
|||||||||||||
|
|||||||||||||
|
To request full article click here. OBJECTIVE: To evaluate published studies regarding the combination of a bisphosphonate and raloxifene in the treatment of osteoporosis. DATA SOURCES: A MEDLINE search (1966–February 2006) was conducted using the search terms osteoporosis, alendronate, risedronate, ibandronate, raloxifene, bisphosphonate, treatment, and selective estrogen-receptor modulators. DATA SYNTHESIS: The results demonstrated a significant increase in lumbar bone mineral density (BMD) and conflicting results in the femoral BMD. Fracture risk was not assessed in either study. CONCLUSIONS: Published trials assessed BMD rather than fracture risk and were limited by methodologic flaws. Due to insufficient clinical outcomes data, combining these antiresorptive treatments cannot be recommended. J Pharm Technol 2006;22:215-20. To request full article click here. |
||||||||||||
|